Tvardi Therapeutics (TVRD) Prepaid Assets (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Prepaid Assets of $345000.0 for Q1 2026, up 50.0% sequentially from $230000.0 in Q4 2025, and down 78.33% YoY from $1.6 million in Q1 2025.
Tvardi Therapeutics (TVRD) Prepaid Assets (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Prepaid Assets for 14 years, with the latest figure at $345000.0 in Q1 2026.
- Quarterly Prepaid Assets fell 78.33% year-over-year to $345000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $345000.0 (down 78.33% YoY) and the FY2025 annual result came in at $230000.0, up 325.93% from the prior year.
- Prepaid Assets climbed to $345000.0 in Q1 2026 per TVRD's latest filing, from $230000.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $17.2 million in Q1 2023 and troughed at $54000.0 in Q4 2024.
- A 5-year average of $3.3 million and a median of $660000.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets jumped 2331.54% in 2022, then tumbled 99.34% in 2024.
- Over 5 years, Prepaid Assets stood at $16.3 million in 2022, then slumped by 49.87% to $8.2 million in 2023, then sank by 99.34% to $54000.0 in 2024, then soared by 325.93% to $230000.0 in 2025, then jumped by 50.0% to $345000.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $345000.0, $230000.0, and $368000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 345,000.00 |
| Dec 31, 2025 | 230,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | 250,000.00 |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | 298,000.00 |
| Mar 31, 2024 | 472,000.00 |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 660,000.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 17.20 Mn |
| Dec 31, 2022 | 16.27 Mn |
| Sep 30, 2022 | 614,000.00 |
| Jun 30, 2022 | 831,000.00 |
| Mar 31, 2022 | 5.11 Mn |
| Dec 31, 2021 | 669,000.00 |
| Sep 30, 2021 | 6.26 Mn |
| Jun 30, 2021 | 8.30 Mn |